Replies to post #322 on Equity Field Notes from temporal sources

[DanWebzster]

ICCC is a animal health biotech with potential for equity to double in value by 2020.

ICCC could gain FDA approval for its revolutionary Mastitis treatment by H1/20.

MAST OUT will not require milk discard as antibiotic treatments do. Milk discard cost an average of $82 per treated cow or about $200mn per year.

ICCC presently generates $11mn p.a. from its treatment for scours in newborn calves. The market for this product expected to grow